Hairy Cell Leukemia Workup
- Author: Emmanuel C Besa, MD; Chief Editor: Koyamangalath Krishnan, MD, FRCP, FACP more...
Laboratory Studies
- The typical hairy cells of hairy cell leukemia are so named because of their characteristic cytoplasmic projections, which appear as fine (hairlike) microvilli when seen by light microscopy, phase-contrast microscopy, and electron microscopy. These are mononuclear cells with eccentric or centrally placed nuclei.
- Hairy cells have a mature B-cell phenotype and typically express single or multiple immunoglobulin light chains and pan–B-cell antigens, such as CD19, CD20, CD22, and CD79b, but not CD21 (late B-cell marker). The cells also typically express CD103, CD11c, and CD25 but usually not CD5, CD10, or CD23. Hairy cells strongly express CD45, seen as a bright signal, with increased forward and side scatter resembling large lymphocytes and monocytes. Immunophenotypic analysis helps distinguish hairy cell leukemia from other low-grade B-cell malignancies. A study by Venkataraman et al confirmed that CD123 and CD103 are useful in the differential diagnosis of B-cell lymphoproliferative disorders.[6]
- Monoclonal BLy-7 has high sensitivity and specificity for HCL. CD22 stains at higher intensity in hairy cells than in normal B cells.[7] Hairy cells can be identified immunophenotypically in 92% of cases, even when the cells represent less than 1% of the circulating lymphocytes.
- Cytochemical evaluation is important for diagnostic confirmation of the morphologic findings. Hairy cells demonstrate strong positivity for tartrate-resistant acid phosphatase (TRAP) staining (see image below). A positive TRAP stain in conjunction with a characteristic bone marrow biopsy is essentially diagnostic of hairy cell leukemia.
Blood film at × 1000 magnification. This image demonstrates tartrate-resistant acid phosphatase (TRAP) activity of lymphocytes. Photographed by U. Woermann, MD, Division of Instructional Media, Institute for Medical Education, University of Bern, Switzerland. - The peripheral blood cell counts show pancytopenia with decreased cell counts in all 3 cell lines.
- Anemia is usually severe and normochromic-normocytic in character.
- Neutropenia and monocytopenia are usually present in hairy cell leukemia, but an elevated white blood cell count (hairy cells) is found in 20% of cases.
- Thrombocytopenia is found in more than 80% of patients.
- The bone marrow aspirate is usually unsuccessful due to a "dry tap." Infiltration of the bone marrow by hairy cell leukemia makes aspirating cells through a needle difficult.
- Clonal cytogenetic abnormalities are present in two thirds of patients, and the involvement of chromosomes 1, 2, 5, 6, 11, 14, 19, and 20 have been described. Chromosome 5 abnormality is most frequent (in 40% of patients) with trisomy 5 and pericentric inversions and interstitial deletions of band 5q13.
Imaging Studies
- Most patients with hairy cell leukemia have massive splenomegaly such that imaging studies are unnecessary to appreciate its presence.
- In milder forms, a liver and spleen scan or ultrasound measurement may detect some mild forms of organomegaly that may be missed by abdominal palpation.
Other Tests
- Difficult cases can be confirmed by using immunophenotypic analysis of the buffy coat cells or by performing electron microscopy on suspected cells.
- Soluble interleukin-2 receptor levels are elevated in patients with hairy cell leukemia and may provide additional supportive data for the diagnosis.
- The somatically acquired V600E mutation of the BRAF gene is present in all patients with hairy cell leukemia and represents a reliable marker.[9] A study by Tiacci et al examined the use of a test for genetics-based diagnosis of hairy cell leukemia. The molecular assay determines the presence of the BRAF-V600E mutation in order to differentiate between hairy cell leukemia and other disorders (eg, splenic marginal zone lymphoma, hairy cell leukemia variant). The study found that the molecular assay was a powerful tool for enhancing the diagnostic accuracy.[10]
Histologic Findings
The findings of pancytopenia and splenomegaly in the presence of circulating cells that are TRAP positive and a dry bone marrow aspirate with biopsy material showing infiltration with a mononuclear cells that have a fried-egg appearance are diagnostic of hairy cell leukemia.
Bouroncle BA, Wiseman BK, Doan CA. Leukemic reticuloendotheliosis. Blood. Jul 1958;13(7):609-30. [Medline]. [Full Text].
Cannon T, Mobarek D, Wegge J, Tabbara IA. Hairy cell leukemia: current concepts. Cancer Invest. Oct 2008;26(8):860-5. [Medline].
Arcaini L, Zibellini S, Boveri E, Riboni R, Rattotti S, Varettoni M, et al. The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms. Blood. Nov 9 2011;[Medline].
Zinzani PL, Magagnoli M, Bendandi M, et al. Long-term follow-up of hairy cell leukemia patients treated with 2-chlorodeoxyadenosine. Haematologica. Sep 2000;85(9):922-5. [Medline]. [Full Text].
Orsi L, Delabre L, Monnereau A, et al. Occupational exposure to pesticides and lymphoid neoplasms among men: results of a French case-control study. Occup Environ Med. Nov 18 2008;epub ahead of print. [Medline].
Venkataraman G, Aguhar C, Kreitman RJ, Yuan CM, Stetler-Stevenson M. Characteristic CD103 and CD123 expression pattern defines hairy cell leukemia: usefulness of CD123 and CD103 in the diagnosis of mature B-cell lymphoproliferative disorders. Am J Clin Pathol. Oct 2011;136(4):625-30. [Medline].
Sherman MJ, Hanson CA, Hoyer JD. An assessment of the usefulness of immunohistochemical stains in the diagnosis of hairy cell leukemia. Am J Clin Pathol. Sep 2011;136(3):390-9. [Medline].
Katayama I. Bone marrow in hairy cell leukemia. Hematol Oncol Clin North Am. Dec 1988;2(4):585-602. [Medline].
Arcaini L, Zibellini S, Boveri E, et al. The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms. Blood. Jan 5 2012;119(1):188-91. [Medline].
Tiacci E, Schiavoni G, Forconi F, et al. Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation. Blood. Jan 5 2012;119(1):192-5. [Medline].
Piro LD, Carrera CJ, Carson DA, Beutler E. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med. Apr 19 1990;322(16):1117-21. [Medline].
Goodman GR, Burian C, Koziol JA, Saven A. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol. Mar 1 2003;21(5):891-6. [Medline]. [Full Text].
Ganzel C, Gatt ME, Maly A, Ben-Yehuda D, Goldschmidt N. High incidence of skin rash in patients with hairy cell leukemia treated with cladribine. Leuk Lymphoma. Oct 31 2011;[Medline].
Chadha P, Rademaker AW, Mendiratta P, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience. Blood. Jul 1 2005;106(1):241-6. [Medline]. [Full Text].
Ravandi F, Jorgensen JL, O'Brien SM, et al. Eradication of minimal residual disease in hairy cell leukemia. Blood. Jun 15 2006;107(12):4658-62. [Medline]. [Full Text].
Kreitman RJ, Arons E, Stetler-Stevenson M, Fitzgerald DJ, Wilson WH, Pastan I. Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia. Leuk Lymphoma. Jun 2011;52 Suppl 2:82-6. [Medline].
Flinn IW, Kopecky KJ, Foucar MK, et al. Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood. Nov 1 2000;96(9):2981-6. [Medline]. [Full Text].
Au WY, Klasa RJ, Gallagher R, et al. Second malignancies in patients with hairy cell leukemia in british columbia: a 20-year experience. Blood. Aug 15 1998;92(4):1160-4. [Medline]. [Full Text].
Kurzrock R, Strom SS, Estey E, et al. Second cancer risk in hairy cell leukemia: analysis of 350 patients. J Clin Oncol. May 1997;15(5):1803-10. [Medline].
Forconi F. Hairy cell leukaemia: biological and clinical overview from immunogenetic insights. Hematol Oncol. Jun 2011;29(2):55-66. [Medline].
Glaspy JA, Baldwin GC, Robertson PA, et al. Therapy for neutropenia in hairy cell leukemia with recombinant human granulocyte colony-stimulating factor. Ann Intern Med. Nov 15 1988;109(10):789-95. [Medline].
Monnereau A, Orsi L, Troussard X, Berthou C, et al. Cigarette smoking, alcohol drinking, and risk of lymphoid neoplasms: results of a French case-control study. Cancer Causes Control. Dec 2008;19(10):1147-60. [Medline].
Ratain MJ, Golomb HM, Vardiman JW, et al. Relapse after interferon alfa-2b therapy for hairy-cell leukemia: analysis of prognostic variables. J Clin Oncol. Nov 1988;6(11):1714-21. [Medline].

